Dublin, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The "Mucopolysaccharidosis Type I (Hurler Syndrome) R&D Pipeline Analysis Report, H2-2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

The Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline guide presents complete overview of drugs currently being developed for Mucopolysaccharidosis Type I (Hurler Syndrome). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline candidate.
Research and Development progress along with latest news related to each of the Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline candidates is included.

Major companies participating in therapeutic development of Mucopolysaccharidosis Type I (Hurler Syndrome) are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Mucopolysaccharidosis Type I (Hurler Syndrome) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Mucopolysaccharidosis Type I (Hurler Syndrome) clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Key Topics Covered:

I. Key Findings

1. Companies Investing in Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline include
Number of Companies with Mucopolysaccharidosis Type I (Hurler Syndrome) projects in pre clinical Development
Number of Companies with Mucopolysaccharidosis Type I (Hurler Syndrome) projects in Clinical Development
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Americas
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Europe
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Asia Pacific
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Agents in pre clinical/ Discovery stage of Development
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Agents in Clinical Development stage
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline agents

II. Insights into Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline -

1. Disease Overview
Introduction to Mucopolysaccharidosis Type I (Hurler Syndrome)
Symptoms and Causes of Mucopolysaccharidosis Type I (Hurler Syndrome)
Treatment or Prevention Options for Mucopolysaccharidosis Type I (Hurler Syndrome)
Other Details
2. Phase wise Pipeline Compounds
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Pre Clinical/ Discovery stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Phase 1 stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Phase 2 stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Phase 3 stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Pre Registration stage Drugs
3. Company wise Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Compounds
4. Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline by Mechanism of Action

III. Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Compound Details

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Company Briefs

V. Latest News and Developments in Global Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Market

VI. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2bm8n6/mucopolysaccharido?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.